Skip to main content
Trending storyHistorical stories

Alethio Therapeutics raises €80.46M Series A for blood cancer drugs

1 reports1 report sources11 days agoUpdate

Get up to speed on this story

AI Summary

Alethio Therapeutics, an Abingdon-on-Thames biopharma spun out of the University of Oxford in 2021, closed an oversubscribed €80.46 million ($90 million/£67 million) Series A. Sofinnova Partners and RA Capital co-led the round, with founding investor Oxford Science Enterprises and support from Cancer Research Horizons and the University of Oxford. The company says it will use the capital to become a clinical-stage business, taking its lead programme ATX-011 through Phase 1/2a studies in essential thrombocythaemia and to Phase 3 readiness, while advancing other myeloproliferative neoplasm programmes toward IND submission.

AI-generated from reports · 9 days agoUpdate

Report timeline

Follow the reports to understand different sides of the story.

Nov 6
  1. EU-StartupsTop Deals
    Oxford spin-out Alethio Therapeutics raises €80.46M Series A for targeted blood cancer therapies

    Alethio Therapeutics, an Abingdon-on-Thames biopharma spun out of the University of Oxford in 2021.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing